345 related articles for article (PubMed ID: 16574667)
1. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL.
McKenzie MD; Dudek NL; Mariana L; Chong MM; Trapani JA; Kay TW; Thomas HE
Int Immunol; 2006 Jun; 18(6):837-46. PubMed ID: 16574667
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways.
Dudek NL; Thomas HE; Mariana L; Sutherland RM; Allison J; Estella E; Angstetra E; Trapani JA; Santamaria P; Lew AM; Kay TW
Diabetes; 2006 Sep; 55(9):2412-8. PubMed ID: 16936188
[TBL] [Abstract][Full Text] [Related]
3. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
4. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF
J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728
[TBL] [Abstract][Full Text] [Related]
5. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes.
Barral AM; Thomas HE; Ling EM; Darwiche R; Rodrigo E; Christen U; Ejrnaes M; Wolfe T; Kay TW; von Herrath MG
J Autoimmun; 2006 Nov; 27(3):166-73. PubMed ID: 17045460
[TBL] [Abstract][Full Text] [Related]
6. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice.
Nakamoto Y; Guidotti LG; Pasquetto V; Schreiber RD; Chisari FV
J Immunol; 1997 Jun; 158(12):5692-7. PubMed ID: 9190918
[TBL] [Abstract][Full Text] [Related]
7. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction.
Chong MM; Chen Y; Darwiche R; Dudek NL; Irawaty W; Santamaria P; Allison J; Kay TW; Thomas HE
J Immunol; 2004 May; 172(9):5714-21. PubMed ID: 15100317
[TBL] [Abstract][Full Text] [Related]
8. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis.
Bachmann MF; Ohteki T; Faienza KM; Zakarian A; Kägi D; Speiser DE; Ohashi PS
J Immunol; 1997 Nov; 159(9):4165-70. PubMed ID: 9379009
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
10. A critical role for granzyme B, in addition to perforin and TNFalpha, in alloreactive CTL-induced mouse pancreatic beta cell death.
Sutton VR; Estella E; Li C; Chen M; Thomas HE; Kay TW; Trapani JA
Transplantation; 2006 Jan; 81(2):146-54. PubMed ID: 16436955
[TBL] [Abstract][Full Text] [Related]
11. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
[TBL] [Abstract][Full Text] [Related]
12. FADDdel-GFP modified mouse insulinoma cells counteract the cytotoxicity of reactive T cells.
Hu P; Wang G; Zhu X; Yang J; Zhu H; Xu Z; Liao W; Liu X; Xu F; Yin J; Shen GX
Cell Mol Immunol; 2004 Oct; 1(5):383-6. PubMed ID: 16285899
[TBL] [Abstract][Full Text] [Related]
13. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
[TBL] [Abstract][Full Text] [Related]
14. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
15. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
[TBL] [Abstract][Full Text] [Related]
16. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
17. IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.
Amrani A; Verdaguer J; Thiessen S; Bou S; Santamaria P
J Clin Invest; 2000 Feb; 105(4):459-68. PubMed ID: 10683375
[TBL] [Abstract][Full Text] [Related]
18. IL-1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms.
Smith DJ; McGuire MJ; Tocci MJ; Thiele DL
J Immunol; 1997 Jan; 158(1):163-70. PubMed ID: 8977187
[TBL] [Abstract][Full Text] [Related]
19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
